BRISTOL Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL, and what generic alternatives to BRISTOL drugs are available?
BRISTOL has one hundred and sixteen approved drugs.
There are fifty-five US patents protecting BRISTOL drugs.
There are one thousand six hundred and ninety-five patent family members on BRISTOL drugs in fifty-eight countries and three hundred and eleven supplementary protection certificates in nineteen countries.
Summary for BRISTOL
International Patents: | 1695 |
US Patents: | 55 |
Tradenames: | 93 |
Ingredients: | 81 |
NDAs: | 116 |
Drug Master File Entries: | 1 |
Patent Litigation for BRISTOL: | See patent lawsuits for BRISTOL |
PTAB Cases with BRISTOL as patent owner: | See PTAB cases with BRISTOL as patent owner |
Drugs and US Patents for BRISTOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | ULTRACEF | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 062376-003 | Mar 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | RX | Yes | No | 8,198,262*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Bristol Myers Squibb | SERZONE | nefazodone hydrochloride | TABLET;ORAL | 020152-001 | Dec 22, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-002 | Jul 24, 2015 | DISCN | Yes | No | 8,629,171 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | 9,597,409*PED | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Bristol Myers Squibb | PRAVIGARD PAC (COPACKAGED) | aspirin; pravastatin sodium | TABLET;ORAL | 021387-004 | Jun 24, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Bristol Myers Squibb | HALOG | halcinonide | OINTMENT;TOPICAL | 018125-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BRISTOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | SUSTIVA | efavirenz | TABLET;ORAL | 021360-001 | Feb 1, 2002 | 5,663,169*PED | ⤷ Sign Up |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | 8,626,531 | ⤷ Sign Up |
Bristol Myers Squibb | PRAVACHOL | pravastatin sodium | TABLET;ORAL | 019898-003 | Oct 31, 1991 | 4,346,227*PED | ⤷ Sign Up |
Bristol Myers Squibb | MEGACE | megestrol acetate | SUSPENSION;ORAL | 020264-001 | Sep 10, 1993 | 5,338,732 | ⤷ Sign Up |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 8,626,531 | ⤷ Sign Up |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 8,315,886 | ⤷ Sign Up |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | 9,056,120 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
➤ Subscribe | Capsules | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2017-02-08 |
➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
International Patents for BRISTOL Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20150064245 | ⤷ Sign Up |
Japan | 5830005 | ⤷ Sign Up |
China | 105025893 | ⤷ Sign Up |
Croatia | P20190100 | ⤷ Sign Up |
Cyprus | 1118292 | ⤷ Sign Up |
Finland | 2291080 | ⤷ Sign Up |
Costa Rica | 10582 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BRISTOL Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049506 | 300780 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COBICISTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527 |
1169038 | 300567 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 - 009 20061120 |
1951684 | C202130029 | Spain | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, O UN HIDRATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR MONOHIDRATO DE DIHIDROCLORURO DE FEDRATINIB; NATIONAL AUTHORISATION NUMBER: EU/1/20/1514; DATE OF AUTHORISATION: 20210208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1514; DATE OF FIRST AUTHORISATION IN EEA: 20210208 |
0925294 | SPC/GB07/047 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619 |
2487163 | CA 2017 00003 | Denmark | ⤷ Sign Up | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG ATAZANAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER ATAZANAVIRSULFAT; REG. NO/DATE: EU/1/15/1025/001-002 20150715 |
1453521 | 15C0050 | France | ⤷ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129 |
0582455 | 2008/016 | Ireland | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF EFAVIRENZ AND EMTRICTABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/07/430/001 20071213 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.